Euthymics Bioscience, Inc. Closes $24 Million Series A Financing And Completes Acquisition Of Dov Pharmaceutical

Company Will Develop a Novel Triple Reuptake Inhibitor Antidepressant for the Largest Single Segment of Patients with Major Depression

 

2010.07.22 Press Release – Euthymics Series A